Estimated Total Annual Burden Hours: 500.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated June 19, 1996.

Larry Guerrero,

Director, Office of Information Management Services.

[FR Doc. 96–16050 Filed 6–24–96; 8:45 am]

BILLING CODE 4184–01–M

Submission of OMB Review; Comment Request

Title: Objective Work Plan, ANA Program Narrative, Application for Federal Assistance.

OMB No.: 0980–0204.

Description: The information collected by Program Narrative; Application for Federal Assistance, the Objective Work Plan, is needed to properly administer and monitor the Administration for Native Americans' (ANA) Program's competitive areas—Social and Economic Development Strategies (SEDS), ANA Reservation and Enhancement, and ANA Mitigation of Environmental Impacts to Indian Lands Due to Department of Defense Activities by providing information in an application for a grant award. This data is used by legislative-mandated Native American review panels, and ANA, as the basis for recommendations for the decisions to award competitive ANA grants.

Respondents: State, Local or Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
OWP	571	1	29.5	17,800

Estimated Total Annual Burden Hours: 17,800.

Additional Information: Copies of the proposed collection may be obtained by writing to the Administration or Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: June 19, 1996.

Larry Guerrero,

Director, Office of Information Management Services.

[FR Doc. 96–16051 Filed 6–24–96; 8:45 am]

BILLING CODE 4184–01–M

Submission for OMB Review; Comment Request

Title: Objective Progress Report (OPR), Administration for Native Americans.

OMB No.: 0980–0155.

Description: The information collected by the Objective Progress Report on an ANA grantee's project progress is needed to properly administer and monitor the progress of Administration for Native American' competitive areas grants—Social and Economic Development Strategies (SEDS), ANA Environmental Enhancement, and ANA Mitigation of Environment Impacts to Indian Lands due to Department of Defense Activities. This information is used to perform legislatively required Federal financial and program management oversight functions.

Respondents: State, Local and Tribal Govt.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
OPR	250	2	2	1,000

Estimated Total Annual Burden Hours: 1,000.

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, SW., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: June 19, 1996.

Larry Guerrero,

Director, Office of Information Management Services.

[FR Doc. 96–16070 Filed 6–24–96; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETINGS: The following advisory committee meetings are announced:

Vaccines and Related Biological Products Advisory Committee

Date, time, and place. July 10 and 11, l996, 8 a.m., Holiday Inn—Bethesda, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Type of meeting and contact person. Closed committee deliberations, July 10, l996, 8 a.m. to 10 a.m., open committee discussion, 10 a.m. to 3:45 p.m.; open public hearing, 3:45 p.m. to 4:30 p.m., unless public participation does not last that long; closed committee deliberations, July 11, 1996, 8 a.m. to 8:45 a.m.; open committee discussion, 8:45 a.m. to 12 m.; open public hearing, 12 m. to 12:30 p.m., unless public participation does not last that long; open committee discussion, 12:30 p.m. to 2 p.m.; closed committee deliberations, 2 p.m. to 3:30 p.m.; Nancy T. Cherry or Sandy M. Salins, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Vaccines and Related Biological Products Advisory Committee, code 12388. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of vaccines intended for use in the diagnosis, prevention, or treatment of human diseases.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before July 3, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. On July 10, 1996, the committee will review safety and efficacy data pertaining to a diphtheria/tetanus/acellular pertussis vaccine manufactured by SmithKline Beecham. On July 11, 1996, the committee will review safety and comparative immunogenicity data pertaining to a liquid version of an Haemophilus b conjugate vaccine manufactured by Merck & Co. The committee will also hear a briefing on proposed changes in the polio vaccine recommendations, and a briefing on a research program in the Division of Viral Products.

Closed committee deliberations. On July 10 and 11, l996, the committee will review trade secret and/or confidential commercial information relevant to pending product licensing applications or amendments. These portions of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)). On July 11, l996, the committee will also review data of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(6)).

Circulatory System Devices Panel of the Medical Devices Advisory Committee

Date, time, and place. July 15, 1996, 7:30 a.m., Corporate Bldg., conference room 020B, 9200 Corporate Blvd., Rockville, MD. A limited number of overnight accommodations have been reserved at the Courtyard by Marriott, 2500 Research Blvd., Rockville, MD. Attendees requiring overnight accommodations may contact the hotel at 301–670–6700, and reference the FDA Panel meeting block. Reservations will be confirmed at the group rate based on availability. Attendees with a disability requiring special accommodations should contact Shirley Meeks, Conference Management, 301–594–1283, ext. 113. The availability of appropriate accommodations cannot be assured unless prior notification is received.

Type of meeting and contact person. Closed committee deliberations, 7:30 a.m. to 8:30 a.m.; open public hearing, 8:30 a.m. to 9:30 a.m., unless public participation does not last that long; open committee discussion, 9:30 a.m. to 3:30 p.m.; Ramiah Subramanian, Center for Devices and Radiological Health (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8320, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), Circulatory System Devices Panel, code 12625. Please call the hotline for information concerning any possible changes.

General function of the committee. The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data,